FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3152319534> ?p ?o ?g. }

• W3152319534 endingPage "1366" @default.
• W3152319534 startingPage "1353" @default.
• W3152319534 abstract "Abstract STUDY QUESTION How is endometrial epithelial receptivity, particularly adhesiveness, regulated at the luminal epithelial surface for embryo implantation in the human? SUMMARY ANSWER Podocalyxin (PCX), a transmembrane protein, was identified as a key negative regulator of endometrial epithelial receptivity; specific downregulation of PCX in the luminal epithelium in the mid-secretory phase, likely mediated by progesterone, may act as a critical step in converting endometrial surface from a non-receptive to an implantation-permitting state. WHAT IS KNOWN ALREADY The human endometrium must undergo major molecular and cellular changes to transform from a non-receptive to a receptive state to accommodate embryo implantation. However, the fundamental mechanisms governing receptivity, particularly at the luminal surface where the embryo first interacts with, are not well understood. A widely held view is that upregulation of adhesion-promoting molecules is important, but the details are not well characterized. STUDY DESIGN, SIZE, DURATION This study first aimed to identify novel adhesion-related membrane proteins with potential roles in receptivity in primary human endometrial epithelial cells (HEECs). Further experiments were then conducted to determine candidates’ in vivo expression pattern in the human endometrium across the menstrual cycle, regulation by progesterone using cell culture, and functional importance in receptivity using in vitro human embryo attachment and invasion models. PARTICIPANTS/MATERIALS, SETTING, METHODS Primary HEECs (n = 9) were isolated from the proliferative phase endometrial tissue, combined into three pools, subjected to plasma membrane protein enrichment by ultracentrifugation followed by proteomics analysis, which led to the discovery of PCX as a novel candidate of interest. Immunohistochemical analysis determined the in vivo expression pattern and cellular localization of PCX in the human endometrium across the menstrual cycle (n = 23). To investigate whether PCX is regulated by progesterone, the master driver of endometrial differentiation, primary HEECs were treated in culture with estradiol and progesterone and analyzed by RT-PCR (n = 5) and western blot (n = 4). To demonstrate that PCX acts as a negative regulator of receptivity, PCX was overexpressed in Ishikawa cells (a receptive line) and the impact on receptivity was determined using in vitro attachment (n = 3–5) and invasion models (n = 4–6), in which an Ishikawa monolayer mimicked the endometrial surface and primary human trophoblast spheroids mimicked embryos. Mann–Whitney U-test and ANOVA analyses established statistical significance at *P ≤ 0.05 and **P ≤ 0.01. MAIN RESULTS AND THE ROLE OF CHANCE PCX was expressed on the apical surface of all epithelial and endothelial cells in the non-receptive endometrium, but selectively downregulated in the luminal epithelium from the mid-secretory phase coinciding with the establishment of receptivity. Progesterone was confirmed to be able to suppress PCX in primary HEECs, suggesting this hormone likely mediates the downregulation of luminal PCX in vivo for receptivity. Overexpression of PCX in Ishikawa monolayer inhibited not only the attachment but also the penetration of human embryo surrogates, demonstrating that PCX acts as an important negative regulator of epithelial receptivity for implantation. LIMITATIONS, REASONS FOR CAUTION Primary HEECs isolated from the human endometrial tissue contained a mixture of luminal and glandular epithelial cells, as further purification into subtypes was not possible due to the lack of specific markers. Future study would need to investigate how progesterone differentially regulates PCX in endometrial epithelial subtypes. In addition, this study used primary human trophoblast spheroids as human embryo mimics and Ishikawa as endometrial epithelial cells in functional models, future studies with human blastocysts and primary epithelial cells would further validate the findings. WIDER IMPLICATIONS OF THE FINDINGS The findings of this study add important new knowledge to the understanding of human endometrial remodeling for receptivity. The identification of PCX as a negative regulator of epithelial receptivity and the knowledge that its specific downregulation in the luminal epithelium coincides with receptivity development may provide new avenues to assess endometrial receptivity and individualize endometrial preparation protocols in assisted reproductive technology (ART). The study also discovered PCX as progesterone target in HEECs, identifying a potentially useful functional biomarker to monitor progesterone action, such as in the optimization of progesterone type/dose/route of administration for luteal support. STUDY FUNDING/COMPETING INTEREST(S) Study funding was obtained from ESHRE, Monash IVF and NHMRC. LR reports potential conflict of interests (received grants from Ferring Australia; personal fees from Monash IVF Group and Ferring Australia; and non-financial support from Merck Serono, MSD, and Guerbet outside the submitted work. LR is also a minority shareholder and the Group Medical Director for Monash IVF Group, a provider of fertility preservation services). The remaining authors have no potential conflict of interest to declare. TRIAL REGISTRATION NUMBER NA." @default.
• W3152319534 created "2021-04-13" @default.
• W3152319534 creator A5001059672 @default.
• W3152319534 creator A5006391071 @default.
• W3152319534 creator A5020086934 @default.
• W3152319534 creator A5022132341 @default.
• W3152319534 creator A5028521609 @default.
• W3152319534 creator A5041126609 @default.
• W3152319534 creator A5044666756 @default.
• W3152319534 creator A5044684679 @default.
• W3152319534 creator A5044754249 @default.
• W3152319534 creator A5047744546 @default.
• W3152319534 creator A5055082504 @default.
• W3152319534 creator A5060599347 @default.
• W3152319534 creator A5064439771 @default.
• W3152319534 creator A5070853689 @default.
• W3152319534 creator A5090686062 @default.
• W3152319534 date "2021-04-02" @default.
• W3152319534 modified "2023-10-17" @default.
• W3152319534 title "Podocalyxin is a key negative regulator of human endometrial epithelial receptivity for embryo implantation" @default.
• W3152319534 cites W1978640205 @default.
• W3152319534 cites W1989096955 @default.
• W3152319534 cites W1993866784 @default.
• W3152319534 cites W1994532803 @default.
• W3152319534 cites W2006327505 @default.
• W3152319534 cites W2006852393 @default.
• W3152319534 cites W2009730891 @default.
• W3152319534 cites W2014979849 @default.
• W3152319534 cites W2019378351 @default.
• W3152319534 cites W2028595192 @default.
• W3152319534 cites W2036906023 @default.
• W3152319534 cites W2037199116 @default.
• W3152319534 cites W2043911138 @default.
• W3152319534 cites W2049184335 @default.
• W3152319534 cites W2059322436 @default.
• W3152319534 cites W2073288227 @default.
• W3152319534 cites W2085226735 @default.
• W3152319534 cites W2087906992 @default.
• W3152319534 cites W2091561827 @default.
• W3152319534 cites W2098035469 @default.
• W3152319534 cites W2107490653 @default.
• W3152319534 cites W2124476281 @default.
• W3152319534 cites W2130463115 @default.
• W3152319534 cites W2133438308 @default.
• W3152319534 cites W2133885587 @default.
• W3152319534 cites W2134982308 @default.
• W3152319534 cites W2134999659 @default.
• W3152319534 cites W2141802887 @default.
• W3152319534 cites W2144297584 @default.
• W3152319534 cites W2145819979 @default.
• W3152319534 cites W2153653822 @default.
• W3152319534 cites W2154414030 @default.
• W3152319534 cites W2155642459 @default.
• W3152319534 cites W2156291136 @default.
• W3152319534 cites W2156292936 @default.
• W3152319534 cites W2156589304 @default.
• W3152319534 cites W2162983307 @default.
• W3152319534 cites W2166351608 @default.
• W3152319534 cites W2204640292 @default.
• W3152319534 cites W2278115522 @default.
• W3152319534 cites W2283899119 @default.
• W3152319534 cites W2399828993 @default.
• W3152319534 cites W2506944489 @default.
• W3152319534 cites W2521861472 @default.
• W3152319534 cites W2563535135 @default.
• W3152319534 cites W2730631639 @default.
• W3152319534 cites W2732463977 @default.
• W3152319534 cites W2743164141 @default.
• W3152319534 cites W2747531951 @default.
• W3152319534 cites W2782826790 @default.
• W3152319534 cites W2809059566 @default.
• W3152319534 cites W2810915570 @default.
• W3152319534 cites W2894356471 @default.
• W3152319534 cites W2896463158 @default.
• W3152319534 cites W2900408745 @default.
• W3152319534 cites W2904965579 @default.
• W3152319534 cites W2910025422 @default.
• W3152319534 cites W2910899393 @default.
• W3152319534 cites W2927173694 @default.
• W3152319534 cites W2932004470 @default.
• W3152319534 cites W2965181622 @default.
• W3152319534 cites W4233076171 @default.
• W3152319534 doi "https://doi.org/10.1093/humrep/deab032" @default.
• W3152319534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33822049" @default.
• W3152319534 hasPublicationYear "2021" @default.
• W3152319534 type Work @default.
• W3152319534 sameAs 3152319534 @default.
• W3152319534 citedByCount "16" @default.
• W3152319534 countsByYear W31523195342021 @default.
• W3152319534 countsByYear W31523195342022 @default.
• W3152319534 countsByYear W31523195342023 @default.
• W3152319534 crossrefType "journal-article" @default.
• W3152319534 hasAuthorship W3152319534A5001059672 @default.
• W3152319534 hasAuthorship W3152319534A5006391071 @default.
• W3152319534 hasAuthorship W3152319534A5020086934 @default.
• W3152319534 hasAuthorship W3152319534A5022132341 @default.
• W3152319534 hasAuthorship W3152319534A5028521609 @default.
• W3152319534 hasAuthorship W3152319534A5041126609 @default.

• next